Atomic AI vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Atomic AI is a San Francisco biotech using AI and structural biology to design RNA-targeting therapeutics; founded in 2021 by Raphael Townshend (AlphaFold co-contributor); raised $35M Series A in 2022;
About
Atomic AI is a biotechnology company founded in 2021 and headquartered in San Francisco, California, at the intersection of artificial intelligence and RNA biology. The company was co-founded by Raphael Townshend, a key contributor to machine learning methods for molecular structure prediction including work related to AlphaFold, reflecting the founding team's deep expertise in applying AI to three-dimensional molecular structure. Atomic AI's platform combines machine learning with structural biology to understand and predict RNA structure and RNA-protein interactions — a capability central to designing drugs that target RNA molecules rather than proteins.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.